rg1068
Intraductal Papillary Mucinous Neoplasms
Massachusetts General Hospitalprotein_peptidePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Intraductal Papillary Mucinous Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM National Cancer Institute (NCI) | Phase 3 | BB |
Capecitabine National Cancer Institute (NCI) | Phase 3 | BB |
Secretin Fundacion Clinic per a la Recerca Biomédica | Phase 3 | B |
Sulindac Duke University | Phase 2 | CCC |
Vitamin E Delta Tocotrienol H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | CCC |
Ferumoxytol OHSU Knight Cancer Institute | N/A | D |
ly4337713 Eli Lilly and Company | Phase 1 | NR |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →